Conference item
ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 128.8KB)
-
- Publisher copy:
- 10.1093/annonc/mdx440.051
Authors
Funding
Celgene Corporation
More from this funder
Bibliographic Details
- Publisher:
- Oxford University Press Publisher's website
- Journal:
- annals of oncology Journal website
- Volume:
- 28
- Issue:
- suppl_5
- Pages:
- 635-636
- Host title:
- Annals of Oncology
- Publication date:
- 2017-09-18
- Acceptance date:
- 2017-07-27
- Event location:
- Madrid, SPAIN
- DOI:
- ISSN:
-
1569-8041 and 0923-7534
- Source identifiers:
-
738403
Item Description
- Pubs id:
-
pubs:738403
- UUID:
-
uuid:a956854d-1faa-47bf-aa60-bcc314b711d6
- Local pid:
- pubs:738403
- Deposit date:
- 2018-02-15
Terms of use
- Copyright holder:
- © European Society for Medical Oncology 2017 Published by Oxford University Press All rights reserved
- Copyright date:
- 2017
- Notes:
- This is the author accepted manuscript following peer review version of the article. The final version is available online from Oxford University Press at: 10.1093/annonc/mdx440.051
If you are the owner of this record, you can report an update to it here: Report update to this record